MannKind Corporation (MNKD)
NASDAQ: MNKD · Real-Time Price · USD
6.85
+0.55 (8.73%)
Dec 20, 2024, 4:00 PM EST - Market closed
MannKind Employees
As of December 31, 2023, MannKind had 414 total employees, including 411 full-time and 3 part-time employees. The number of employees increased by 19 or 4.81% compared to the previous year.
Employees
414
Change (1Y)
19
Growth (1Y)
4.81%
Revenue / Employee
$645,411
Profits / Employee
$52,094
Market Cap
1.89B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
National HealthCare | 13,123 |
Astrana Health | 1,800 |
Certara | 1,391 |
Galapagos NV | 1,123 |
GoodRx Holdings | 694 |
ImmunityBio | 628 |
Recursion Pharmaceuticals | 500 |
Neumora Therapeutics | 124 |
MNKD News
- 4 days ago - MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets - Seeking Alpha
- 5 days ago - MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®) - GlobeNewsWire
- 10 days ago - CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India - GlobeNewsWire
- 6 weeks ago - MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call Transcript - Seeking Alpha
- 6 weeks ago - MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - MannKind to Present at 2024 UBS Healthcare Conference - GlobeNewsWire
- 6 weeks ago - MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases - GlobeNewsWire
- 7 weeks ago - MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024 - GlobeNewsWire